Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. co-CEO AmirAli Talasaz reported a combination of stock option exercises and share sales tied to the Talasaz and Eskandari 2017 Family Trust. On June 26 and June 29, 2026, the trust sold an aggregate 260,000 shares of common stock in open-market transactions at weighted-average prices around $150–$153 per share, executed across multiple price ranges.
On the same dates, stock options to acquire a total of 254,832 shares of common stock were exercised at a $4.18 per-share exercise price, converting derivative awards into common shares. The common stock and options are reported as held directly or indirectly, with a significant portion attributed to the Talasaz and Eskandari 2017 Family Trust.
GH reporting person AmirAli Talasaz submitted a Form 144 disclosing secondary sales of Common Stock. The filing lists two dispositions: 50,000 shares sold on 05/12/2026 for $5,016,000 and 210,000 shares sold on 05/20/2026 for $23,076,690. The broker named is Stifel Nicolaus & Company Inc. The filing also lists holdings/issuable amounts tied to earlier grants: 5,168 Founder Shares (09/22/2018) and 254,832 shares related to an equity compensation event (04/23/2017).
Guardant Health, Inc. submission of a Form 144 notifies the SEC of proposed sale of 2000 shares of Common Stock on 06/26/2026 related to an Employee Stock Option Exercise via a broker payment for cashless exercise.
The excerpt also lists recent dispositions by Meghan V. Joyce: 10,000 shares on 06/03/2026, 6,203 shares on 06/22/2026, and 2,000 shares on 06/24/2026, with proceeds shown in the filing for each transaction.
Guardant Health, Inc. affiliate filed a Form 144 reporting the proposed sale of 2,000 shares of common stock on 06/24/2026 associated with an employee stock option exercise and a broker payment for a cashless exercise. The filing also lists prior sales by Meghan V. Joyce of 10,000 shares on 06/03/2026 for $1,269,809.00 and 6,203 shares on 06/22/2026 for $812,604.00. Shares outstanding are shown as 132,599,929 as of 06/24/2026.
Guardant Health director Tariq Musa sold 1,951 shares of Common Stock in an open-market transaction. The shares were sold at an average price of $131.16 per share. After this sale, Musa directly holds 11,048 Guardant Health shares, indicating he retains a significant ongoing equity position in the company.
Guardant Health, Inc. director Myrtle S. Potter reported an open-market sale of Common Stock. She sold 1,556 shares on June 22, 2026 at an average price of $131.16 per share. After this transaction, she directly holds 20,971 Guardant Health shares.
Guardant Health director Roberto Mignone reported routine equity compensation activity, exercising restricted stock units (RSUs) into common shares. On May 21, 2026 and June 21, 2026, RSU conversions of 264 shares each delivered a total of 528 common shares at a stated price of $0.00 per share.
After these transactions, Mignone directly held 9,482 shares of Guardant Health common stock and 7,392 RSUs. Footnotes explain that the RSU award was granted on November 8, 2024 and vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported routine equity compensation activity. On June 17, 2026, he exercised 4,203 Restricted Stock Units into the same number of common shares following full vesting tied to the 2026 Annual Meeting of Stockholders.
He also received a new grant of 2,711 Restricted Stock Units that will vest in full on the one-year anniversary of the grant date, June 17, 2026, or on the date of Guardant Health’s next annual meeting of stockholders, whichever is earlier. Following these transactions, Musa directly holds 12,999 shares of common stock and 2,711 Restricted Stock Units, with no shares sold.
Guardant Health director Myrtle S. Potter reported routine equity compensation activity. On June 17, 2026, she exercised 4,203 Restricted Stock Units, acquiring the same number of common shares and bringing her direct common stock holdings to 22,527 shares. A prior restricted stock unit award vested in full on the 2026 Annual Meeting date. She also received a new grant of 2,711 Restricted Stock Units, which will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Roberto Mignone reported routine equity compensation activity. On June 17, 2026, he exercised restricted stock units covering 4,203 shares of Common Stock, bringing his direct Common Stock holdings to 8,954 shares after the transaction.
On the same date, he received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of Common Stock. According to the footnotes, the RSU award that generated the 4,203 shares vested in full on the date of the 2026 Annual Meeting of Stockholders, while the new 2,711-unit award will vest in full on the earlier of the one-year anniversary of its June 17, 2026 grant date or the Company’s next annual meeting of stockholders.